Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Hepatitis C virus genotype 1 NS5A variants in Japanese patients.

Vilchez RA.

Lancet Infect Dis. 2015 Dec;15(12):1378. doi: 10.1016/S1473-3099(15)00404-1. Epub 2015 Nov 16. No abstract available.

PMID:
26607122
2.

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.

Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L, Dekhtyar T, Hall C, Vilchez RA, Pilot-Matias T, Collins C.

Antimicrob Agents Chemother. 2015 Nov;59(11):6807-15. doi: 10.1128/AAC.01229-15. Epub 2015 Aug 17.

3.

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.

Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, Varunok P, Morillas RM, Hall C, Mobashery N, Redman R, Pilot-Matias T, Vilchez RA, Hézode C.

Gastroenterology. 2015 Oct;149(4):971-80.e1. doi: 10.1053/j.gastro.2015.07.001. Epub 2015 Jul 11.

4.

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R.

Hepatology. 2015 Oct;62(4):1037-46. doi: 10.1002/hep.27972. Epub 2015 Aug 25.

5.

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.

Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S.

Lancet. 2015 Jun 20;385(9986):2502-9. doi: 10.1016/S0140-6736(15)60159-3. Epub 2015 Mar 31.

PMID:
25837829
6.

Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.

Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L Jr, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H.

Hepatology. 2015 May;61(5):1523-32. doi: 10.1002/hep.27705. Epub 2015 Mar 23.

7.

An interferon-free antiviral regimen for HCV after liver transplantation.

Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X.

N Engl J Med. 2014 Dec 18;371(25):2375-82. doi: 10.1056/NEJMoa1408921. Epub 2014 Nov 11.

8.

Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.

Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA.

J Infect. 2015 Feb;70(2):197-205. doi: 10.1016/j.jinf.2014.09.008. Epub 2014 Sep 22.

9.

Molecular diagnostics in the management of chronic hepatitis C: key considerations in the era of new antiviral therapies.

Cobb B, Heilek G, Vilchez RA.

BMC Infect Dis. 2014;14 Suppl 5:S8. doi: 10.1186/1471-2334-14-S5-S8. Epub 2014 Sep 5. Review.

10.

Comparison of two quantitative real-time CMV-PCR tests calibrated against the 1st WHO international standard for viral load monitoring of renal transplant patients.

Mannonen L, Loginov R, Helanterä I, Dumoulin A, Vilchez RA, Cobb B, Hirsch HH, Lautenschlager I.

J Med Virol. 2014 Apr;86(4):576-84. doi: 10.1002/jmv.23733. Epub 2013 Sep 11.

PMID:
24026892
11.

HCV RNA viral load assessments in the era of direct-acting antivirals.

Cobb B, Pockros PJ, Vilchez RA, Vierling JM.

Am J Gastroenterol. 2013 Apr;108(4):471-5. doi: 10.1038/ajg.2012.248. Review.

PMID:
23552304
12.

CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients.

Cardeñoso L, Pinsky BA, Lautenschlager I, Aslam S, Cobb B, Vilchez RA, Hirsch HH.

J Clin Virol. 2013 Feb;56(2):108-12. doi: 10.1016/j.jcv.2012.10.001. Epub 2012 Nov 10.

PMID:
23146665
13.

An international multicenter performance analysis of cytomegalovirus load tests.

Hirsch HH, Lautenschlager I, Pinsky BA, Cardeñoso L, Aslam S, Cobb B, Vilchez RA, Valsamakis A.

Clin Infect Dis. 2013 Feb;56(3):367-73. doi: 10.1093/cid/cis900. Epub 2012 Oct 24.

14.

Ethnic differences in polyomavirus simian virus 40 seroprevalence among women in Houston, Texas.

Wong C, Vilchez RA, Quiroz J, Adam E, Butel JS.

J Infect. 2013 Jan;66(1):67-74. doi: 10.1016/j.jinf.2012.08.014. Epub 2012 Aug 30.

15.

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.

McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM.

J Clin Virol. 2012 Oct;55(2):134-9. doi: 10.1016/j.jcv.2012.06.021. Epub 2012 Jul 21.

PMID:
22824230
16.

Polyomavirus JC urinary shedding in kidney and liver transplant recipients associated with reduced creatinine clearance.

Kusne S, Vilchez RA, Zanwar P, Quiroz J, Mazur MJ, Heilman RL, Mulligan D, Butel JS.

J Infect Dis. 2012 Sep 15;206(6):875-80. doi: 10.1093/infdis/jis469. Epub 2012 Jul 16.

17.

Novel clinical trial designs and HIV-1 RNA assessments with end-point and real-time PCR tests.

Vilchez RA.

AIDS. 2012 Jul 17;26(11):1453-4. doi: 10.1097/QAD.0b013e3283550dc8. No abstract available.

PMID:
22767348
18.

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.

Caseiro MM, Nelson M, Diaz RS, Gathe J, de Andrade Neto JL, Slim J, Solano A, Netto EM, Mak C, Shen J, Greaves W, Dunkle LM, Vilchez RA, Zeinecker J.

J Infect. 2012 Oct;65(4):326-35. doi: 10.1016/j.jinf.2012.05.008. Epub 2012 May 24.

PMID:
22634184
19.

An update on treatment of hepatitis C virus genotype 1 infection and viral load assessments.

Cobb B, Vilchez RA.

Hepatology. 2012 Mar;55(3):979-80; author reply 980-1. doi: 10.1002/hep.25516. No abstract available.

PMID:
22161994
20.

Evolution in the sensitivity of quantitative HIV-1 viral load tests.

Cobb BR, Vaks JE, Do T, Vilchez RA.

J Clin Virol. 2011 Dec;52 Suppl 1:S77-82. doi: 10.1016/j.jcv.2011.09.015. Epub 2011 Oct 28. Review.

PMID:
22036041
21.

Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation.

Thomas LD, Milstone AP, Vilchez RA, Zanwar P, Butel JS, Dummer JS.

Transplantation. 2009 Aug 15;88(3):360-6. doi: 10.1097/TP.0b013e3181ae5ff9.

22.

Viral regulatory region effects on vertical transmission of polyomavirus SV40 in hamsters.

Patel NC, Halvorson SJ, Sroller V, Arrington AS, Wong C, Smith EO, Vilchez RA, Butel JS.

Virology. 2009 Mar 30;386(1):94-101. doi: 10.1016/j.virol.2008.12.040. Epub 2009 Jan 31.

23.

SV40 lymphomagenesis in Syrian golden hamsters.

McNees AL, Vilchez RA, Heard TC, Sroller V, Wong C, Herron AJ, Hamilton MJ, Davis WC, Butel JS.

Virology. 2009 Feb 5;384(1):114-24. doi: 10.1016/j.virol.2008.10.035. Epub 2008 Nov 28.

24.

Detection of polyomavirus SV40 in tonsils from immunocompetent children.

Patel NC, Vilchez RA, Killen DE, Zanwar P, Sroller V, Eldin KW, López-Terrada D, Butel JS.

J Clin Virol. 2008 Sep;43(1):66-72. doi: 10.1016/j.jcv.2008.04.011. Epub 2008 Jun 9.

25.

Influence of the viral regulatory region on tumor induction by simian virus 40 in hamsters.

Sroller V, Vilchez RA, Stewart AR, Wong C, Butel JS.

J Virol. 2008 Jan;82(2):871-9. Epub 2007 Oct 31.

26.

Polyomavirus SV40 and AIDS-related systemic non-Hodgkin's lymphoma.

Vilchez RA, Butel JS.

Cancer Treat Res. 2007;133:215-40. Review. No abstract available.

PMID:
17672043
27.

Viruses from nonhuman primates.

Vilchez RA.

Emerg Infect Dis. 2006 Nov;12(11):1802-3; author reply 1803. No abstract available.

28.

A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients.

Thomas LD, Vilchez RA, White ZS, Zanwar P, Milstone AP, Butel JS, Dummer S.

J Infect Dis. 2007 Feb 1;195(3):442-9. Epub 2006 Dec 22.

PMID:
17205484
29.
30.

Simian virus 40 in posttransplant lymphoproliferative disorders.

Vilchez RA, Jauregui MP, Hsi ED, Novoa-Takara L, Chang CC.

Hum Pathol. 2006 Sep;37(9):1130-6. Epub 2006 Jul 20.

PMID:
16938517
31.

Limitations of epidemiological and serologic studies addressing simian virus 40 and non-Hodgkin's lymphoma.

Vilchez RA.

Cancer Invest. 2006 Apr-May;24(3):333-6. No abstract available.

PMID:
16809164
32.

Re: Jarrett. Viruses and lymphoma/leukaemia. J Pathol 2006;208:176-186.

Vilchez RA.

J Pathol. 2006 Jul;209(3):420-1; author reply 422-4. No abstract available.

PMID:
16639695
33.

Lymphoproliferative disorders in Costa Rica and simian virus 40.

Meneses A, Lopez-Terrada D, Zanwar P, Killen DE, Monterroso V, Butel JS, Vilchez RA.

Haematologica. 2005 Dec;90(12):1635-42.

34.

Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma.

Vilchez RA, Lopez-Terrada D, Middleton JR, Finch CJ, Killen DE, Zanwar P, Jorgensen JL, Butel JS.

Virology. 2005 Nov 10;342(1):38-46. Epub 2005 Aug 24.

35.

Specific and quantitative detection of human polyomaviruses BKV, JCV, and SV40 by real time PCR.

McNees AL, White ZS, Zanwar P, Vilchez RA, Butel JS.

J Clin Virol. 2005 Sep;34(1):52-62.

PMID:
16087125
36.

Polyomavirus SV40 infections in Kazakhstan.

Nurgalieva ZZ, Wong C, Zhangabylov AK, Omarbekova ZE, Graham DY, Vilchez RA, Butel JS.

J Infect. 2005 Feb;50(2):142-8.

PMID:
15667916
37.

Standardized detection of SV40 by real time quantitative polymerase chain reaction.

Vilchez RA.

Haematologica. 2005 Jan;90(1):6. No abstract available.

PMID:
15644307
38.

Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles.

Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ, Vilchez RA, McGregor D, Jorgensen JL.

Mod Pathol. 2005 Jun;18(6):806-15. Erratum in: Mod Pathol. 2005 Jun;18(6):873. Medeiros, Leonard J [corrected to Medeiros, L Jeffrey].

39.

Differential ability of two simian virus 40 strains to induce malignancies in weanling hamsters.

Vilchez RA, Brayton CF, Wong C, Zanwar P, Killen DE, Jorgensen JL, Butel JS.

Virology. 2004 Dec 5;330(1):168-77.

40.

Emergent human pathogen simian virus 40 and its role in cancer.

Vilchez RA, Butel JS.

Clin Microbiol Rev. 2004 Jul;17(3):495-508, table of contents. Review.

41.

Association between SV40 and non-Hodgkin's lymphoma.

Butel JS, Vilchez RA, Jorgensen JL, Kozinetz CA.

Leuk Lymphoma. 2003;44 Suppl 3:S33-9. Review.

PMID:
15202523
42.

Re: Lack of serologic evidence for prevalent simian virus 40 infection in humans.

Vilchez RA, Butel JS.

J Natl Cancer Inst. 2004 Apr 21;96(8):633; author reply 633-4. No abstract available.

PMID:
15100343
43.

Polyomavirus simian virus 40 infection associated with nephropathy in a lung-transplant recipient.

Milstone A, Vilchez RA, Geiger X, Fogo AB, Butel JS, Dummer S.

Transplantation. 2004 Apr 15;77(7):1019-24.

PMID:
15087764
44.

An overview of the biology and viral pathogenesis of lymphoproliferative disorders in HIV-infected patients.

Vilchez RA, Butel JS.

Res Initiat Treat Action. 2003 Summer;9(1):14-8. No abstract available.

PMID:
14971361
45.

Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy.

Ling PD, Vilchez RA, Keitel WA, Poston DG, Peng RS, White ZS, Visnegarwala F, Lewis DE, Butel JS.

Clin Infect Dis. 2003 Nov 1;37(9):1244-9. Epub 2003 Sep 23.

PMID:
14557970
46.

Polyomavirus SV40 infection and lymphomas in Spain.

Vilchez RA, Butel JS.

Int J Cancer. 2003 Nov 10;107(3):505-6; author reply 507-8. No abstract available.

47.

Re: Cancer incidence in Denmark following exposure to poliovirus vaccine contaminated with simian virus 40.

Vilchez RA, Arrington AS, Butel JS.

J Natl Cancer Inst. 2003 Aug 20;95(16):1249; author reply 1250. No abstract available.

PMID:
12928352
48.

SV40 in human brain cancers and non-Hodgkin's lymphoma.

Vilchez RA, Butel JS.

Oncogene. 2003 Aug 11;22(33):5164-72. Review.

PMID:
12910253
49.

Simian virus 40 and its association with human lymphomas.

Vilchez RA, Butel JS.

Curr Oncol Rep. 2003 Sep;5(5):372-9. Review.

PMID:
12895387
50.

Simian virus 40 in human cancers.

Vilchez RA, Kozinetz CA, Arrington AS, Madden CR, Butel JS.

Am J Med. 2003 Jun 1;114(8):675-84.

PMID:
12798456

Supplemental Content

Loading ...
Support Center